TransMedics Heart Transplant Tool Lands FDA Panel Date After 6-Month Delay
The US agency’s circulatory system devices panel will take up the company’s heart transplant tool in an October virtual session.
You may also be interested in...
The company said the postponement will give the US FDA additional time to review trial data.
FDA approved a PMA supplement to allow TransMedics' Organ Care System (OCS) to be used for the preservation and ex-vivo assessment of lungs that would not be acceptable for transplant if they had been preserved with a standard cold static system.
The US FDA’s decision to allow Medtronic to market the Symplicity Spyral renal denervation (RDN) device sets up a rivalry in the RDN market, as the medtech giant’s offering will come up against ReCor’s Paradise system.